Wang J, Adachi M, Rhoads D E
Department of Biochemistry, Microbiology and Molecular Genetics, University of Rhode Island, Kingston, USA.
Comp Biochem Physiol B Biochem Mol Biol. 1998 Feb;119(2):241-6. doi: 10.1016/s0305-0491(98)01002-5.
This study was designed to determine if a Ca(2+)-dependent, calnaktin-like inhibitor of Na,K-ATPase existed in rat brain and to compare the inhibition of different Na,K-ATPase isozymes in brain, heart and kidney. Based on the size and characteristics of human red blood cell calnaktin, a soluble protein fraction was obtained from rat brain and subjected to ultrafiltration and gel filtration to restrict the proteins to an appropriate molecular range of 6-50 kDa (6/50 fraction) for a crude calnaktin preparation. The 6/50 fraction was reconstituted with semipurified rat brain Na,K-ATPase and resulted in Ca(2+)-dependent inhibition of Na,K-ATPase activity. A 6/50 fraction was also prepared from rat heart ventricles, and, in its presence, Ca(2+)-dependent inhibition of cardiac Na,K-ATPase activity was observed. With brain preparations, the threshold for inhibition was approximately 100 nM free Ca2+, and inhibition was half maximal at 3-10 microM free Ca2+. Different isozymes of Na,K-ATPase were examined using differential sensitivity to ouabain and differential tissue distribution in brain, heart and kidney. The alpha 1 activity was inhibited in all three tissues. The alpha 2 activity of heart and the alpha 2 and/or alpha 3 activity of brain were also inhibited by the brain 6/50 fraction. In synaptosomal preparations from rat forebrain, resting intracellular (intrasynaptosomal) free Ca2+ was close to the threshold for calnaktin-like inhibition. The results are consistent with the presence of a calnaktin-like inhibitor of Na,K-ATPase in rat brain and indicate that calnaktin could be a widespread regulator of the alpha 1 isozyme. In addition, this study provides the first evidence that calnaktin also inhibits the alpha 2 activity of heart and the alpha 2 and/or alpha 3 isozymes of brain.
本研究旨在确定大鼠脑中是否存在一种依赖Ca(2+)的、类似于钙调蛋白的钠钾ATP酶抑制剂,并比较其对脑、心脏和肾脏中不同钠钾ATP酶同工酶的抑制作用。基于人红细胞钙调蛋白的大小和特性,从大鼠脑中获得了一种可溶性蛋白组分,并进行超滤和凝胶过滤,以将蛋白质限制在6 - 50 kDa的合适分子范围内(6/50组分),用于制备粗制钙调蛋白。将6/50组分与半纯化的大鼠脑钠钾ATP酶重组,导致钠钾ATP酶活性出现依赖Ca(2+)的抑制。还从大鼠心室制备了6/50组分,在其存在下,观察到心脏钠钾ATP酶活性出现依赖Ca(2+)的抑制。对于脑制备物,抑制阈值约为100 nM游离Ca2+,在3 - 10 microM游离Ca2+时抑制作用达到半数最大效应。利用对哇巴因的不同敏感性以及在脑、心脏和肾脏中的不同组织分布,对钠钾ATP酶的不同同工酶进行了检测。α1活性在所有三种组织中均受到抑制。心脏的α2活性以及脑的α2和/或α3活性也受到脑6/50组分的抑制。在大鼠前脑的突触体制备物中,静息细胞内(突触体内)游离Ca2+接近钙调蛋白样抑制的阈值。这些结果与大鼠脑中存在钠钾ATP酶的钙调蛋白样抑制剂一致,并表明钙调蛋白可能是α1同工酶的广泛调节剂。此外,本研究首次提供了证据表明钙调蛋白还抑制心脏的α2活性以及脑的α2和/或α3同工酶。